Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-10
2007-04-10
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S468000
Reexamination Certificate
active
10784917
ABSTRACT:
The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1′ position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety. Indolinone compounds that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosoluble indolinone compounds that are tyrosine kinase inhibitors and related products and methods.
REFERENCES:
patent: 2872372 (1959-02-01), Hull
patent: 2968557 (1961-01-01), Burgardt et al.
patent: 4002749 (1977-01-01), Rovnyak
patent: 4053613 (1977-10-01), Rovnyak et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4642309 (1987-02-01), Michel et al.
patent: 4826847 (1989-05-01), Michel et al.
patent: 4853403 (1989-08-01), Shiraishi et al.
patent: 4868304 (1989-09-01), Larock et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5051417 (1991-09-01), Nadler et al.
patent: 5057538 (1991-10-01), Shiraishi et al.
patent: 5089516 (1992-02-01), Shiraishi et al.
patent: 5124347 (1992-06-01), Connor et al.
patent: 5202341 (1993-04-01), Shiraishi et al.
patent: 5206261 (1993-04-01), Kawaguchi et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5322950 (1994-06-01), Sircar et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5374652 (1994-12-01), Buzzetti et al.
patent: 5382593 (1995-01-01), Le Baut
patent: 5397787 (1995-03-01), Buzzetti et al.
patent: 5409949 (1995-04-01), Buzzetti et al.
patent: 5463052 (1995-10-01), Haga et al.
patent: 5786488 (1998-07-01), Tang et al.
patent: 5792783 (1998-08-01), Tang
patent: 5834504 (1998-11-01), Tang et al.
patent: 5840745 (1998-11-01), Buzzetti et al.
patent: 5849710 (1998-12-01), Battistini et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 6130238 (2000-10-01), Tang et al.
patent: 6147106 (2000-11-01), Tang et al.
patent: 6486185 (2002-11-01), McMahon et al.
patent: 6531502 (2003-03-01), Tang et al.
patent: 6906093 (2005-06-01), Tang et al.
patent: 2004/0067531 (2004-04-01), Tang et al.
patent: 286870 (1967-05-01), None
patent: 2012634 (1991-09-01), None
patent: 878539 (1953-06-01), None
patent: 2159360 (1973-06-01), None
patent: 2159361 (1973-06-01), None
patent: 2159362 (1973-06-01), None
patent: 2159363 (1973-06-01), None
patent: 2321656 (1973-11-01), None
patent: 3426419 (1986-01-01), None
patent: 0 252 713 (1988-01-01), None
patent: 0 351 213 (1990-01-01), None
patent: 0 525 472 (1993-02-01), None
patent: 0 566 226 (1993-10-01), None
patent: 0 580 502 (1994-01-01), None
patent: 0 626 377 (1994-11-01), None
patent: 0 632 102 (1995-01-01), None
patent: 0 662 473 (1995-07-01), None
patent: 0 788 890 (1997-08-01), None
patent: 1.398.224 (1965-05-01), None
patent: 2.689.397 (1993-10-01), None
patent: 809691 (1959-03-01), None
patent: 835473 (1960-05-01), None
patent: 65452 (1994-06-01), None
patent: 62-29570 (1987-02-01), None
patent: 62-39564 (1987-02-01), None
patent: 63-141955 (1988-06-01), None
patent: 5-58894 (1993-03-01), None
patent: WO 88/07035 (1988-09-01), None
patent: WO 91/13055 (1991-09-01), None
patent: WO 91/15495 (1991-10-01), None
patent: WO 92/03736 (1992-03-01), None
patent: WO 92/07830 (1992-05-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/21660 (1992-12-01), None
patent: WO 93/01182 (1993-01-01), None
patent: WO 93/23040 (1993-11-01), None
patent: WO 94/03427 (1994-02-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO 95/01349 (1995-01-01), None
patent: WO 95/14667 (1995-06-01), None
patent: WO 95/17181 (1995-06-01), None
patent: WO 95/24190 (1995-09-01), None
patent: WO 96/00226 (1996-01-01), None
patent: WO 96/16964 (1996-06-01), None
patent: WO 96/22976 (1996-08-01), None
patent: WO 96/32380 (1996-10-01), None
patent: WO 96/40116 (1996-12-01), None
patent: WO 97/25986 (1997-07-01), None
patent: WO 97/36867 (1997-10-01), None
patent: WO 98/07695 (1998-02-01), None
patent: WO 98/07835 (1998-02-01), None
patent: WO 98/45708 (1998-10-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 98/56376 (1998-12-01), None
patent: WO 99/10325 (1999-03-01), None
Abramovitch and Hey, “Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles,”J. Chem. Soc. pp. 1697-1703 (1954).
Abramovitch et al., “A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement,”Chemistry and Industry44:1871 (1967).
Abramovitch, Beilstein Reg. No. 236050,J. Chem. Soc., pp. 1697, 1700 (1954).
Akbasak and Suner-Akbasak et al., “Oncogenes: cause or consequence in the development of glial tumors,”J. Neurol. Sci. 111:119-133 (1992).
Andreani et al., “In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones,”Arzneimittel-Forschung Drug Research48 (II): 727-729(1998).
Andreani et al., “Potential antitumor agents. 25[1]. Synthesis and cytotoxic activity of 3-(2-chloro-3-indolylmethlene) 1,3-Dyhydroindol-2-ones,”AntiCancer Research16:3585-3588 (1996).
Andreani et al., “Synthesis and cardiotonic activity of 2-indolinones,”Chemical Abstracts, vol. 113, abstract No. 78106 (1990).
Andreani et al., “Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups,”Eur. J. Med. Chem. 28:653-657 (1993).
Andreani et al., “Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones,”Eur. J. Med. Chem. 27:167-170 (1992).
Andreani et al., “Synthesis of lacatams with potential cardiotonic activity,”Eur. J. Med. Chem. 28:825-829 (1993).
Arteaga et al., “Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice,”J. Clin. Invest. 84:1418-1423 (1989).
Arvidsson et al., “Tyr-716 in the Platelet-Derived Growth Factor β-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation,”Molecular and Cellular Biology14:6715-6726 (1994).
Autrey and Tahk, “The Synthesis and Sterochemistry of Some Isatylideneacetic Acid Derivatives,”Tetrahedron23:901-917 (1967).
Bahner et al., “Benzylideneindenes with Oxygen Attached to the Indene Ring,”J. Med. Chem. 12:721-722 (1969).
Bamfield et al., “Diels-Alder Reactions of Oxindolylideneacetone,”J. Chem. Soc.(C) pp. 1028-1030 (1966).
Baserga, “The insulin-like growth factor I receptor: a key to tumor growth?”Cancer Res. 55:249-252 (1995).
Beilstein Reg. No. 235647 (1997).
Beilstein Reg. No. 252929 (1923).
Blake and Jaques, “Anistropic Effects in alpha-substituted methoxystilbenes,”J. Chem. Soc. Perkin IIpp. 1660-1663 (1973).
Blake and Jacques, “Anistropic Effects in alpha-substituted methoxystilbenes,”Chemical Abstracts, vol. 80, abstract No. 266692 (1974).
Bolen, “Nonreceptor tyrosine protein kinases,”Oncogene8:2025-2031 (1993).
Bolen et al., “The Src family of tyrosine protein kinases in hemopoietic signal transduction,”FASEB J. 6:3403-3409 (1992).
Bonner et al., “Structure and Biological Activity of Human Homologs of theraf/milOncogene,”Molec
Hirth Klaus Peter
McMahon Gerald
Shawver Laura Kay
Sun Connie Li
Tang Peng Cho
Foley & Lardner LLP
Stockton Laura L.
Sugen Inc.
LandOfFree
Indolinone combinatorial libraries and related products and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolinone combinatorial libraries and related products and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolinone combinatorial libraries and related products and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3802569